Showing Results for
- Academic Journals (57)
Search Results
- 57
Academic Journals
- 57
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedTo the editor: The production of induced pluripotent stem (iPS) cell lines from human somatic cells, such as skin fibroblasts, recently reported in your January issue (1) and elsewhere (2-4), opens the exciting new...
- 2From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedDavid R. King has joined $700-million-asset investment firm Quaker BioVentures (Philadelphia) as a venture partner focusing on merger-and-acquisition deals. King spent 26 years at law firm Morgan, Lewis & Bockius and...
- 3From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedNoninvasive, presymptomatic diagnosis will be key to improving the prognosis for pancreatic adenocarcinoma, which has a five-year survival rate of only 3%. To address this need, Faca et al. analyze plasmas from a...
- 4From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedPlans for linking Europe's existing biobanks were unveiled at the European Parliament on May 28. The announcement took stock of the progress made so far toward creating a pan-European Biobanking and Biomolecular...
- 5From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedPrivately held Itero Biopharmaceuticals (San Mateo, CA, USA) has said that as part of a joint venture with Biological E. Ltd. and a $21 million Series A venture financing, the following have been added to the company's...
- 6From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedEvergreening is a practice familiar to many in the pharmaceutical industry. It involves the reformulation of a brand drug so that the manufacturer's patent monopoly and period of market exclusivity can be extended,...
- 7From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedAlthough genetic engineering--the technical ability to edit DNA--has led to impressive biotechnology applications, these generally require many years of work and trial-and-error experiments to implement (1). A concerted...
- 8From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedAnonymous Nat. Biotechnol. 26, 475 (2008); published online May 2008; corrected after print 13 June 2008 In the version of this article initially published, in paragraph 4, the generic name and ligand given for...
- 9From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedSantaris Pharma (Horsholm, Denmark) has announced the appointment of Soren Tulstrup as president and CEO. He takes over as CEO from Keith McCullagh, who is retiring but will remain a member of the board of directors....
- 10From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedThe industry sector involved in 'biopharmaceutical' development, manufacture and marketing is now over 25 years old (or several hundred years old, depending on the definition used), with over 350 marketed products (or...
- 11From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedA mechanism underlying the gastrointestinal damage caused by radiation of the abdomen has been identified, suggesting a new approach to mitigating the toxicity of cancer radiotherapy. A protein called p53 upregulated...
- 12From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedThe next-generation biofuels industry got a boost in May when Congress passed new laws under the 2008 Farm Bill that support the use of lignocellulosic feedstocks. The bill creates a tax credit of $1.01 per gallon of...
- 13From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedTopigen Pharmaceuticals (Montreal) has appointed Jeremy Curnock Cook to its board of directors. Curnock Cook is executive chairman and founder of BioScience Managers Limited and previously created and led the bioscience...
- 14From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedReprogramming of mouse and human somatic cells can be achieved by ectopic expression of transcription factors, but with low efficiencies. We report that DNA methyltransferase and histone deacetylase (HDAC) inhibitors...
- 15From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedVertex Pharmaceuticals (Cambridge, MA, USA) has named Freda C. Lewis-Hall executive vice president, medicines development. She joins Vertex from Bristol-Myers Squibb where she served as senior vice president, US...
- 16From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedNat. Biotechnol. 26, 343-351 (2008); published online 24 February 2008; corrected after print 8 July 2008 In the version of this article initially published, on p.348, column 2, paragraph 2, line 7, the following...
- 17From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedGlucosteroid- and cyclophosphamide-based immunosuppressive therapies show poor efficacy in the treatment of autoantibody-mediated disorders like systemic lupus erythematosus (SLE). Neubert et al. show that the...
- 18From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedAlbumin fusion is being touted as a useful tool to extend the half-life of certain small peptides, so it's no surprise that the field has seen a bloom of activity lately. In May, Bagsvaerd, Denmark-based Novozymes...
- 19From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedTo inhibit arthritis upstream of inflammatory cytokine release and matrix metal loproteinase (MMP) action, we designed de novo a small-molecule inhibitor of c-Fos/activator protein-1 (AP-1) using three-dimensional (3D)...
- 20From: Nature Biotechnology. (Vol. 26, Issue 7) Peer-ReviewedAs with any other groundbreaking experimental treatment, progress of the first dendrimer drug, VivaGel (SPL7013), through the clinic has not been entirely smooth sailing. Last October, VivaGel's manufacturer, Melbourne,...